US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

141.57

-0.3600-0.25%

Post-market: 141.570.00000.00%16:05 EDT

Volume:460.60K

Turnover:64.55M

Market Cap:8.14B

PE:28.01

High:141.69

Open:140.20

Low:138.32

Close:141.93

Loading ...

Overview Company News Filings

CR Boya Projects Significant Net Profit Growth for 2024

CR Construction Secures HK$2 Billion Public Housing Contract in Hong Kong

CR Double-Crane Pharmaceutical's Unit to Build New Industrial Base for 1.48 Billion Yuan

MT Newswires Live

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

'Into Whooperland' Review: The Beauty of the Whooping Crane

Junshi Biosciences Announces Toripalimab’s Approval in Australia

J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug

CR Construction's Chairman Boosts Stakeholding

MT Newswires Live

Chairman Increases Stake in CR Construction Group

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

CR Double-Crane Gets Supplementary Approval for Antibiotic, Sodium Bicarbonate Injection

MT Newswires Live

Protara Highlights Recent Updates and Anticipated 2025 Milestones

GSK Enters Agreement to Acquire IDRx, Inc.

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

New Strong Sell Stocks for January 9th

China Resources Double-Crane Pharmaceutical Gets Listing Approval for Heparin Sodium API

MT Newswires Live

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

Press Release: Crane Company Announces Date for Fourth Quarter 2024 Earnings Release and Teleconference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CR/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":141.57,"timestamp":1744833600000,"preClose":141.93,"halted":0,"volume":460595,"hourTrading":{"tag":"盘后","latestPrice":141.57,"preClose":141.57,"latestTime":"16:05 EDT","volume":29897,"amount":4232518.29,"timestamp":1744833911259},"delay":0,"floatShares":48596385,"shares":57484763,"eps":5.054545,"marketStatus":"Not Yet Opened","change":-0.36,"latestTime":"04-16 16:00:00 EDT","open":140.2,"high":141.685,"low":138.315,"amount":64547605.16073,"amplitude":0.023744,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.054545,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744876800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":141.93,"dividendRate":0.005792,"preHourTrading":{"tag":"盘前","latestPrice":140.52,"preClose":141.93,"latestTime":"08:37 EDT","volume":9,"amount":1267.02,"timestamp":1744807060884},"postHourTrading":{"tag":"盘后","latestPrice":141.57,"preClose":141.57,"latestTime":"16:05 EDT","volume":29897,"amount":4232518.29,"timestamp":1744833911259},"volumeRatio":1.243876,"impliedVol":0.457,"impliedVolPercentile":0.9124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","floatShares":48596385,"roa":"8.53%","roe":"17.87%","lyrEps":5.152097,"volumeRatio":1.243876,"shares":57484763,"dividePrice":0.82,"high":141.685,"amplitude":0.023744,"preClose":141.93,"low":138.315,"week52Low":127.04,"pbRate":"4.97","psRate":"3.82","week52High":188.52,"institutionHeld":0.6875,"latestPrice":141.57,"eps":5.054545,"divideRate":0.005792,"volume":460595,"delay":0,"ttmEps":5.054545,"open":140.2,"prevYearClose":151.75,"prevWeekClose":140.89,"prevMonthClose":153.18,"prevQuarterClose":153.18,"fiveDayClose":147.8,"twentyDayClose":154.89,"sixtyDayClose":162.46,"earningDate":1745769600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CR\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505713455","title":"CR Boya Projects Significant Net Profit Growth for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2505713455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505713455?lang=en_us&edition=fundamental","pubTime":"2025-01-22 17:10","pubTimestamp":1737537011,"startTime":"0","endTime":"0","summary":"China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has provided an announcement. CR Boya Bio-pharmaceutical, a subsidiary of China Resources ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cr-boya-projects-significant-net-profit-growth-for-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cr-boya-projects-significant-net-profit-growth-for-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2505379729","title":"CR Construction Secures HK$2 Billion Public Housing Contract in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2505379729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505379729?lang=en_us&edition=fundamental","pubTime":"2025-01-22 16:39","pubTimestamp":1737535183,"startTime":"0","endTime":"0","summary":"The latest announcement is out from CR Construction Group Holdings Limited ( ($HK:1582) ). CR Construction Group Holdings Limited has announced tha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cr-construction-secures-hk2-billion-public-housing-contract-in-hong-kong?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cr-construction-secures-hk2-billion-public-housing-contract-in-hong-kong?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2505764148","title":"CR Double-Crane Pharmaceutical's Unit to Build New Industrial Base for 1.48 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2505764148","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505764148?lang=en_us&edition=fundamental","pubTime":"2025-01-22 13:58","pubTimestamp":1737525503,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical's  unit, Anhui Shuanghe Pharmaceutical, plans to build a new industrial park for 1.48 billion yuan, according to a Shanghai Stock Exchange disclosure on Wednesday.The construction is part of Anhui Shuanghe's plan to relocate its Sanshan production base to Fanchang District, Wuhu City, China. Construction will begin in February and production will start in January 2028.The planned industrial park will produce 1.15 billion bottles every year, the pharmaceutical company said.The company's shares fell 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0028","BK4161","BK0010","CR","600062","BK0239","BGSX","BK0185","BK0175"],"gpt_icon":0},{"id":"2505278023","title":"Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505278023","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505278023?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:01","pubTimestamp":1737496860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart  in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma . These results were presented at the American Society of Clinical Oncology  Gastrointestinal Annual Cancers Symposium.Ozekibart-related treatment-emergent adverse events  were reported in 84.6% of patients, with most being grade 1 or 2 in severity. Grade ≥3 TEAEs were observed in 30.8% of patients. The most common ozekibart-related TEAEs included nausea, increased alanine aminotransferase, diarrhea, and fatigue, with the majority being low-grade.Ozekibart is a precision-engineered, tetravalent death receptor 5  agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.In Januar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inhibrx-biosciences-announces-preliminary-data-220100477.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inhibrx-biosciences-announces-preliminary-data-220100477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRC","BK4195","CR","LU0266512127.USD","PR","BK4211","INBX","SD","LU0456854461.SGD","BK4161","PFS","BK4213","BK4139"],"gpt_icon":0},{"id":"2504916092","title":"'Into Whooperland' Review: The Beauty of the Whooping Crane","url":"https://stock-news.laohu8.com/highlight/detail?id=2504916092","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504916092?lang=en_us&edition=fundamental","pubTime":"2025-01-17 23:26","pubTimestamp":1737127560,"startTime":"0","endTime":"0","summary":"Five feet tall, with a 7-foot wingspan, the whooping crane is a Pleistocene relic that has somehow survived into the 21st century. Slammed by hunting and habitat loss, whoopers hit a low of 22 individuals in 1941; it's been a slow and arduous conservationist-assisted climb to today's modest peak of 700 birds. \"Into Whooperland\" is the moving story of Michael Forsberg's quest to know a snow-white and ebony bird for which the descriptor \"magnificent\" barely suffices.To make this book, Mr. Forsberg, a photographer from Nebraska, traveled some 50,000 miles in four years along the \"Whooper Highway\" -- the birds' ancient migratory route that stretches from coastal Texas to the Northwest Territories of Canada -- producing 100,000 images, 50 hours of video and filling 10 \"coffee-stained\" journals. Among his most treasured experiences: two brand-new whooping-crane chicks meeting their parents on a massive nest of reeds, a sight that moved him to tears.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2504582641","title":"Junshi Biosciences Announces Toripalimab’s Approval in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2504582641","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504582641?lang=en_us&edition=fundamental","pubTime":"2025-01-17 18:56","pubTimestamp":1737111360,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan.  17, 2025  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/17/3011315/0/en/Junshi-Biosciences-Announces-Toripalimab-s-Approval-in-Australia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","RCC","CR"],"gpt_icon":0},{"id":"2503997485","title":"J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503997485","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503997485?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:43","pubTimestamp":1737031380,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive bladder cancer .The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ , with or without papillary tumors. If approved, TAR-200 will be the first intravesical drug-releasing system in the given indication.The FDA will review this submission under its Real-Time Oncology Review  program.Filings reviewed under the RTOR program enable the agency to start evaluating portions of the application as soon as they are ready, instead of waiting for the entire application to be submitted. This approach has been designed to accelerate the approval process for certain oncology drugs or biologics that aim to address unmet medical needs or provide significant advantages over existing therapies.The RTOR program also works ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/j-j-seeks-fda-nod-124300710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1674673691.USD","IE00B19Z3B42.SGD","LU2106854487.HKD","LU1989772840.SGD","MRK","BK4581","LU0114720955.EUR","LU0070302665.USD","JNJ","LU1934455277.USD","BK4568","IE00BVYPNW00.USD","SG9999014575.USD","LU2347655156.SGD","LU1074936037.SGD","LU0266013472.USD","LU1032955483.USD","LU0208291251.USD","LU0234570918.USD","IE00BN8TJ469.HKD","LU1929549753.HKD","LU0098860793.USD","LU1093756168.USD","IE00BSNM7G36.USD","CR","LU0006306889.USD","LU0265550359.USD","SG9999002224.SGD","BK4533","LU1244550221.USD","LU1732799900.SGD","LU0345769631.USD","LU0106261372.USD","IE00BVYPNV92.GBP","LU0965509283.SGD","IE00BLSP4452.SGD","LU1934455194.USD","LU1934455863.HKD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0234572021.USD","LU0345769128.USD","LU1941712348.USD","LU0792757196.USD","LU0238689110.USD","LU1778281490.HKD","BK4161","IBRX","SG9999013999.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2503969051","title":"CR Construction's Chairman Boosts Stakeholding","url":"https://stock-news.laohu8.com/highlight/detail?id=2503969051","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503969051?lang=en_us&edition=fundamental","pubTime":"2025-01-16 18:39","pubTimestamp":1737023970,"startTime":"0","endTime":"0","summary":"CR Construction's  chairman and executive director Guan Manyu purchased 500,000 ordinary shares of the company for around HK$0.479 apiece on Thursday, a same-day bourse filing said.The shares represent roughly 0.1% of the builder's issued share capital.Following the acquisition, Guan holds a total of 3.5 million, or 0.7%, shares in the firm.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1148","CR","BK4161","01582"],"gpt_icon":0},{"id":"2503296800","title":"Chairman Increases Stake in CR Construction Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2503296800","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503296800?lang=en_us&edition=fundamental","pubTime":"2025-01-16 17:10","pubTimestamp":1737018644,"startTime":"0","endTime":"0","summary":"CR Construction Group Holdings Limited ( ($HK:1582) ) just unveiled an announcement. CR Construction Group Holdings Limited announced that its chai...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chairman-increases-stake-in-cr-construction-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chairman-increases-stake-in-cr-construction-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2503890646","title":"New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503890646","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503890646?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:00","pubTimestamp":1736946000,"startTime":"0","endTime":"0","summary":"Application accepted for U.S. FDA Real-Time Oncology Review  based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1. RARITAN, N.J., Jan. 15, 2025 /PRNewswire/ -- Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration  for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer  with carcinoma in situ , with or without papillary tumors. This submission is being reviewed by the FDA through the Real-Time Oncology Review  program, which allows the FDA to review data before the complete application is formally submitted and helps ensure treatments are available for patients as soon as possible.TAR-200 is an investigational intravesical drug releasing system designed to provide sustained local deliveryof gemcitabine into the bladder. It is placed into the bladder by a healthcare professional ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/drug-application-initiated-u-fda-130000101.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/drug-application-initiated-u-fda-130000101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1506573853.SGD","BK4504","LU0345770308.USD","LU1935042991.SGD","LU1261432733.SGD","IE0034235303.USD","LU1674673428.USD","IE00BGHQF631.EUR","LU0640476718.USD","BK4097","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU2347655156.SGD","SG9999001440.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1585245621.USD","OS","IE00BVYPNW00.USD","LU1732800096.USD","LU1894683348.USD","BK4581","BK4533","BK4588","IE00B19Z3B42.SGD","IE00B4R5TH58.HKD","BK4007","LU1732799900.SGD","IE00B19Z3581.USD","IE00B3PB1722.GBP","BK4161","JNJ","IE000M9KFDE8.USD","LU0320765646.SGD","IE0002270589.USD","LU1032466523.USD","LU0912757837.SGD","LU2133065610.SGD","LU0234570918.USD","LU0882574055.USD","LU1244550221.USD","BCG","CR","LU0889566641.SGD","LU0345769128.USD","SG9999002232.USD","IE00B42XCP33.USD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2503650009","title":"CR Double-Crane Gets Supplementary Approval for Antibiotic, Sodium Bicarbonate Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2503650009","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503650009?lang=en_us&edition=fundamental","pubTime":"2025-01-15 12:46","pubTimestamp":1736916373,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  unit China Resources Double Crane Limin Pharmaceutical  obtained drug supplementary approval for azithromycin dispersible tablets and sodium bicarbonate injection, according to a Wednesday filing with the Shanghai Stock Exchange.The azithromycin dispersible tablets are an antibiotic indicated for mild to moderate infections caused by sensitive strains of specific microorganisms, the filing said.Sodium bicarbonate injections are used to treat metabolic acidosis, alkalize urine, and prevent uric acid kidney stones, among other indications, the filing said.Shares fell 1% during Wednesday's late morning trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0185","BK0188","BK4161","BK0010","BK0175","600062","CR","BK0028","BK0239"],"gpt_icon":0},{"id":"2503130917","title":"Protara Highlights Recent Updates and Anticipated 2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2503130917","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503130917?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008410/0/en/Protara-Highlights-Recent-Updates-and-Anticipated-2025-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4161","CR","BCG"],"gpt_icon":0},{"id":"2503326913","title":"GSK Enters Agreement to Acquire IDRx, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503326913","media":"Business Wire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503326913?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:05","pubTimestamp":1736751900,"startTime":"0","endTime":"0","summary":"Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor  designed to treat gastrointestinal stromal tumours . IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies. Acquisition adds to GSK’s growing portfolio in gastrointestinal  cancers. Tony Wood, Chief Scientific Officer, GSK, said: \"We are excited by the early data from IDRX-42 and its unique ability to target all clinically relevant KIT mutations present in GIST, a major gap in the current standard of care. We look forward to accelerating its development in 2025 to redefine treatment.\". Updated clinical data from StrateGIST 1, an ongoing phase I/Ib trial of IDRX-42 in patients with advanced GIST, were presented in an oral presentation at the Connective Tissue Oncology Society  2024 Annual Meeting. These data show promising anti-tumour activity of IDRX-42 in patients with advanced GIST with a manageable sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsk-enters-agreement-acquire-idrx-070500791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MMAT","LU1829250122.USD","BK4104","BK4585","GSK","BK4532","GSK.UK","BK4141","CR","BK4161","CTOS","BK4588"],"gpt_icon":0},{"id":"2502461865","title":"Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502461865","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502461865?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"-TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC-. -First patient expected to be dosed in SURF302 in Q2 2025-. CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor  biology, announced today that the U.S. Food and Drug Administration  cleared its Investigational New Drug  application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer . This program will be led by newly appointed Dr. Erik Goluboff, SVP, Clinical Development of TYRA, who brings more than thirty years of experience as an academic urologic oncologist, principal investigator, practicing urologist and most recently Principal Medical Lead for GU/GI cancers at Genentech/Roche.Dr. Goluboff joins","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tyra-biosciences-receives-ind-clearance-130000689.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tyra-biosciences-receives-ind-clearance-130000689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","BK4211","PFS","BK4563","BK4153","BK4503","QD","TYRA","BK4139","BK4161","ACH","CR","BK4166"],"gpt_icon":0},{"id":"2502048896","title":"INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments","url":"https://stock-news.laohu8.com/highlight/detail?id=2502048896","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502048896?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:04","pubTimestamp":1736427840,"startTime":"0","endTime":"0","summary":"PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advanceof upcoming investor meetings.\"Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for patients suffering from a devastating rare disease and delivering on the promise of DNA medicines,\" said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. \"Our top priorities for the coming year are the submission of our biologics license application  for INO-3107 and preparing to expedite the launch of the product commercially, should it be approved. We also look forward to making progress with our pipeline thro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inovio-highlights-anticipated-2025-milestones-130400901.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inovio-highlights-anticipated-2025-milestones-130400901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0868494708.USD","LU0868494617.USD","LU2264538146.SGD","LU1064131342.USD","LU0149725797.USD","BK4520","CAT","LU0971096721.USD","BK4516","BK4568","IE00B1BXHZ80.USD","BK4139","LU0882574139.USD","BK4006","BK4161","CR","INO","BK4149","LU1363072403.SGD","LU1917777945.USD","IE00BZ1G4Q59.USD","LU0942090050.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0170899867.USD","BK4597","BK4588","BK4585","LU2106854487.HKD","CMC","IE00BHPRN162.USD","LU0267386448.USD","LU1974910355.USD","LU1988902786.USD","LU2237438978.USD","IE00BD6J9T35.USD","BK4583","BK4532","LU2023250504.SGD"],"gpt_icon":0},{"id":"2502099058","title":"New Strong Sell Stocks for January 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2502099058","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502099058?lang=en_us&edition=fundamental","pubTime":"2025-01-09 16:35","pubTimestamp":1736411700,"startTime":"0","endTime":"0","summary":"Here are three stocks added to the Zacks Rank #5  List today:. Baidu, Inc.BIDU is an online marketing and cloud services company. The Zacks Consensus Estimate for its current year earnings has been revised 5.2% downward over the last 60 days.Central Garden & Pet CompanyCENTA is a pet products company. The Zacks Consensus Estimate for its current year earnings has been revised 7.5% downward over the last 60 days.Crane CompanyCR is an engineered industrial products company.The Zacks Consensus Estimate for its current year earnings has been revised 6.3% downward over the last 60 days.Want the latest recommendations from Zacks Investment Research?Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Central Garden & Pet Company  : Free Stock Analysis Report. To read this article on Zacks.com click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-sell-stocks-january-9th-083500200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","LU0359201612.USD","BK4574","BK4585","BK4587","BK4077","CR","BK4548","BK4504","CENTA","LU0640798160.USD","IE00B0JY6N72.USD","LU1115378108.SGD","BK4531","BIDU","BK4552","LU0173614495.USD","LU0287142896.SGD","BK4514","BK4579","BK4018","BK4588","LU0359202008.SGD","BK4161","BK4526","LU1023057109.AUD"],"gpt_icon":1},{"id":"2502050811","title":"China Resources Double-Crane Pharmaceutical Gets Listing Approval for Heparin Sodium API","url":"https://stock-news.laohu8.com/highlight/detail?id=2502050811","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502050811?lang=en_us&edition=fundamental","pubTime":"2025-01-09 13:51","pubTimestamp":1736401879,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  subsidiary Tiandong Pharmaceutical obtained listing approval of China's medical products administrator for its heparin sodium active pharmaceutical ingredient.Heparin sodium is an anticoagulant used for preventing and treating blood clots, according to a Thursday filing with the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0028","600062","BK6520","BK0188","BK0010","BK4161","BK6100","CR","BK0239","OTX.SI","BK0185"],"gpt_icon":0},{"id":"2501719058","title":"BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2501719058","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501719058?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:20","pubTimestamp":1736320800,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International . The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence responded to treatment. The preliminary data demonstrates that the combination treatment is well tolerated with the two enrolled patients already showing clinical responses. One patient has obtained a complete response , and one patient shows a partial response . Patient enrollment remains on schedule. Further Phase 2a data are expected by mid-2025.In addition, the Phase 1/2a study of BI-1206 in combination with MSD's  anti-PD-1 therapy KEYTRUDA  in heavily pre-treated patients with solid tumors continues to progress. The subcutaneous administration of BI-1206 has been well-tolerated with no notable injection reactions. Given the beneficial safety and tolerability profile observed to date, an additional dose cohort with increased dose frequency has been added to the Phase 1 part to further characterize t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-announces-promising-initial-efficacy-072000078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","MRK","BOVNF","LU1037948541.HKD","SG9999015341.SGD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU0070302665.USD","LU0965509101.SGD","IE00BMPRXQ63.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU1983299246.USD","BK4007","LU1066051811.HKD","LU2468319806.SGD","LU1023059063.AUD","IE000M9KFDE8.USD","BK4585","LU1571399168.USD","SG9999014559.SGD","LU2023250843.SGD","LU0965509283.SGD","CR","LU1585245621.USD","LU1934455194.USD","SD","LU1917777945.USD","LU1061106388.HKD","IE00BMPRXR70.SGD","LU2461242641.AUD","LU0234572021.USD","LU0208291251.USD","LU0203345920.USD","LU0006306889.USD","LU0265550359.USD","LU1291159041.SGD","SG9999014575.USD","PR","LU0122379950.USD","LU0861579265.USD","LU1066051498.USD","LU1699723380.USD","LU0211331839.USD","LU1116320737.USD","LU1989772923.USD","IE0009355771.USD","LU1037948897.HKD","SG9999015358.SGD"],"gpt_icon":1},{"id":"2501050719","title":"BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501050719","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501050719?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:20","pubTimestamp":1736320800,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International . BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response with no notable adverse events even at the highest doses tested.Phase 1 part B evaluating BI-1910 in combination with MSD's anti-PD-1 therapy, KEYTRUDA  initiated. As reported in September 2024, preliminary results from the BI-1808 monotherapy study showed that three out of four evaluable patients achieved partial response  in the CTCL cohort of patients who had progressed after standard therapy. These responses are currently ongoing and deepening. New clinical sites have been opened and the enrollment rate in this c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-announces-promising-data-bi-072000027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948897.HKD","CR","LU0203345920.USD","LU1061106388.HKD","LU0234572021.USD","MRK","LU0211331839.USD","LU1934455277.USD","LU0861579265.USD","PR","LU0965509283.SGD","SG9999015358.SGD","LU2023250843.SGD","LU1699723380.USD","LU0070302665.USD","IE0009355771.USD","LU1066051811.HKD","LU0208291251.USD","LU2461242641.AUD","LU1934455194.USD","LU0265550359.USD","SG9999014575.USD","IE000M9KFDE8.USD","LU0122379950.USD","BOVNF","IE0002141913.USD","LU1066051498.USD","LU1291159041.SGD","LU1571399168.USD","LU1983299246.USD","SG9999014559.SGD","BK4585","IE00B4R5TH58.HKD","LU1023059063.AUD","LU0289739699.SGD","LU0965509010.AUD","LU1037948541.HKD","LU0965509101.SGD","SG9999002224.SGD","LU1116320737.USD","LU2468319806.SGD","LU1585245621.USD","SD","LU1917777945.USD","IE00B1BXHZ80.USD","LU1989772923.USD","BK4007","SG9999015341.SGD","LU0006306889.USD","BK4516"],"gpt_icon":0},{"id":"2501783376","title":"Press Release: Crane Company Announces Date for Fourth Quarter 2024 Earnings Release and Teleconference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501783376","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501783376?lang=en_us&edition=fundamental","pubTime":"2025-01-07 23:04","pubTimestamp":1736262240,"startTime":"0","endTime":"0","summary":"Crane Company  announces the following schedule and teleconference information for its fourth quarter 2024 earnings release:. Earnings Release: January 27, 2025 after close of market by public. distribution and the Crane Company website at www.craneco.com.Teleconference: January 28, 2025 at 10:00 AM  hosted by Max H.Mitchell, President & CEO, Alex Alcala, Executive Vice President & COO,and Richard A. Maue, Executive Vice President & CFO. The call can be. accessed in a listen-only mode via the Company's website www.craneco.com.An accompanying slide presentation will also be available on the. Web Replay: Will be available on the Company's website shortly after. Crane Company has delivered innovation and technology-led solutions to its customers since its founding in 1855. Today, Crane is a leading manufacturer of highly engineered components for challenging, mission-critical applications focused on the aerospace, defense, space and process industry end markets. The Company is comprised o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CR\",params:#limit:5,,,undefined,":[{"date":"2025-04-28","symbol":"CR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":1.29,"defaultRemindTime":1745870400000,"name":null,"time":"Post Market","dateTimestamp":1745812800000,"actualEps":null},{"date":"2025-02-28","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-12"},{"market":"US","date":"2025-01-27","symbol":"CR","fiscalQuarterEnding":"2024/12","expectedEps":1.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1737954000000,"reportTimeType":"post","actualEps":1.26},{"date":"2024-11-29","symbol":"CR","amount":0.205,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-29","defaultRemindTime":1732890600000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-11","payableDate":"2024-11-29","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-11"},{"date":"2024-10-28","symbol":"CR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":1.31,"defaultRemindTime":1730145600000,"name":null,"time":"Post Market","dateTimestamp":1730088000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CR\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":"2017-02-28","paymentDate":"2017-03-09","value":0.33,"currency":"USD"},{"executeDate":"2017-05-26","recordDate":"2017-05-31","paymentDate":"2017-06-09","value":0.33,"currency":"USD"},{"executeDate":"2017-08-29","recordDate":"2017-08-31","paymentDate":"2017-09-08","value":0.33,"currency":"USD"},{"executeDate":"2017-11-29","recordDate":"2017-11-30","paymentDate":"2017-12-08","value":0.33,"currency":"USD"},{"executeDate":"2018-02-27","recordDate":"2018-02-28","paymentDate":"2018-03-09","value":0.35,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.6667,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CR","date":"2025-04-15","current":27.562257,"percent":0.603252,"low":8.74154,"twenty":14.045235,"median":24.451163,"eighty":35.764062,"high":224.415426,"avg":33.932176,"sd":39.657844,"marketCap":8122597011},"quantilePoints":[{"date":"2020-04-17","current":23.548949,"twenty":14.741964,"median":18.685627,"eighty":23.870847,"marketCap":3139074897},{"date":"2020-04-24","current":22.63042,"twenty":14.741964,"median":18.772876,"eighty":23.870847,"marketCap":3016635006},{"date":"2020-05-01","current":26.230548,"twenty":14.741964,"median":18.950122,"eighty":24.584825,"marketCap":2982413319},{"date":"2020-05-08","current":27.449269,"twenty":14.741964,"median":18.999018,"eighty":24.821141,"marketCap":3120981901},{"date":"2020-05-15","current":24.160252,"twenty":14.741964,"median":19.07024,"eighty":24.906887,"marketCap":2747020666},{"date":"2020-05-22","current":26.439617,"twenty":14.741964,"median":19.160985,"eighty":25.341628,"marketCap":3006184499},{"date":"2020-05-29","current":28.413028,"twenty":14.741964,"median":19.216082,"eighty":25.710674,"marketCap":3230561239},{"date":"2020-06-05","current":33.588768,"twenty":14.741964,"median":19.237422,"eighty":26.160178,"marketCap":3819042872},{"date":"2020-06-12","current":28.05608,"twenty":14.741964,"median":19.280168,"eighty":26.565059,"marketCap":3189976299},{"date":"2020-06-19","current":28.040782,"twenty":14.741964,"median":19.30144,"eighty":26.931579,"marketCap":3188236945},{"date":"2020-06-26","current":28.73428,"twenty":14.741964,"median":19.376127,"eighty":27.12269,"marketCap":3267087686},{"date":"2020-07-02","current":29.529764,"twenty":14.741964,"median":19.392132,"eighty":27.321969,"marketCap":3357534124},{"date":"2020-07-10","current":27.913301,"twenty":14.741964,"median":19.430021,"eighty":27.459735,"marketCap":3173742323},{"date":"2020-07-17","current":30.717889,"twenty":14.741964,"median":19.444135,"eighty":27.610101,"marketCap":3492623996},{"date":"2020-07-24","current":30.891264,"twenty":14.741964,"median":19.472413,"eighty":27.833259,"marketCap":3512336681},{"date":"2020-07-31","current":87.533402,"twenty":14.74899,"median":19.495965,"eighty":27.94019,"marketCap":3282502591},{"date":"2020-08-07","current":93.258585,"twenty":14.767286,"median":19.525503,"eighty":28.009625,"marketCap":3497196945},{"date":"2020-08-14","current":94.264361,"twenty":14.787765,"median":19.544175,"eighty":28.04746,"marketCap":3534913520},{"date":"2020-08-21","current":87.719084,"twenty":14.813662,"median":19.570486,"eighty":28.081529,"marketCap":3289465651},{"date":"2020-08-28","current":90.040104,"twenty":14.83771,"median":19.594842,"eighty":28.170784,"marketCap":3376503903},{"date":"2020-09-04","current":88.260655,"twenty":14.871894,"median":19.605519,"eighty":28.267865,"marketCap":3309774577},{"date":"2020-09-11","current":84.237554,"twenty":14.936445,"median":19.626415,"eighty":28.310525,"marketCap":3158908274},{"date":"2020-09-18","current":81.978428,"twenty":15.011846,"median":19.656053,"eighty":28.373051,"marketCap":3074191042},{"date":"2020-09-25","current":76.779343,"twenty":15.041272,"median":19.669528,"eighty":28.409968,"marketCap":2879225359},{"date":"2020-10-02","current":76.965025,"twenty":15.066218,"median":19.682881,"eighty":28.47471,"marketCap":2886188419},{"date":"2020-10-09","current":80.137085,"twenty":15.081973,"median":19.70422,"eighty":28.560476,"marketCap":3005140696},{"date":"2020-10-16","current":84.253027,"twenty":15.124703,"median":19.713849,"eighty":28.62779,"marketCap":3159488529},{"date":"2020-10-23","current":85.320697,"twenty":15.162424,"median":19.729877,"eighty":28.703268,"marketCap":3199526125},{"date":"2020-10-30","current":136.527006,"twenty":15.223621,"median":19.752233,"eighty":28.737446,"marketCap":2948983334},{"date":"2020-11-06","current":142.122596,"twenty":15.260409,"median":19.772138,"eighty":28.792366,"marketCap":3069848070},{"date":"2020-11-13","current":165.258207,"twenty":15.260409,"median":19.790516,"eighty":28.85843,"marketCap":3569577265},{"date":"2020-11-20","current":177.390952,"twenty":15.260409,"median":19.802914,"eighty":28.931965,"marketCap":3831644553},{"date":"2020-11-27","current":191.003299,"twenty":15.260409,"median":19.824132,"eighty":28.993533,"marketCap":4125671266},{"date":"2020-12-04","current":198.293707,"twenty":15.260409,"median":19.834923,"eighty":29.072788,"marketCap":4283144070},{"date":"2020-12-11","current":204.884666,"twenty":15.277405,"median":19.845593,"eighty":29.204431,"marketCap":4425508783},{"date":"2020-12-18","current":208.059087,"twenty":15.319129,"median":19.880269,"eighty":29.408025,"marketCap":4494076277},{"date":"2020-12-24","current":206.848503,"twenty":15.339718,"median":19.900532,"eighty":29.534806,"marketCap":4467927656},{"date":"2020-12-31","current":208.919947,"twenty":15.365764,"median":19.915811,"eighty":29.796111,"marketCap":4512670852},{"date":"2021-01-08","current":218.147289,"twenty":15.386249,"median":19.927575,"eighty":30.133245,"marketCap":4711981450},{"date":"2021-01-15","current":217.178822,"twenty":15.463133,"median":19.955186,"eighty":30.348098,"marketCap":4691062553},{"date":"2021-01-22","current":216.990509,"twenty":15.518993,"median":19.983043,"eighty":30.612845,"marketCap":4686994990},{"date":"2021-01-29","current":24.296226,"twenty":15.546124,"median":20.000911,"eighty":30.612845,"marketCap":4397616921},{"date":"2021-02-05","current":26.22567,"twenty":15.604175,"median":20.036867,"eighty":30.612845,"marketCap":4746846277},{"date":"2021-02-12","current":26.752174,"twenty":15.64869,"median":20.047071,"eighty":30.612845,"marketCap":4842143473},{"date":"2021-02-19","current":27.198418,"twenty":15.679949,"median":20.069656,"eighty":30.612845,"marketCap":4922913657},{"date":"2021-02-26","current":26.948508,"twenty":15.757032,"median":20.101665,"eighty":30.612845,"marketCap":4877680001},{"date":"2021-03-05","current":28.764142,"twenty":16.078184,"median":20.131636,"eighty":30.613864,"marketCap":5206309765},{"date":"2021-03-12","current":30.119103,"twenty":16.146147,"median":20.17181,"eighty":30.613864,"marketCap":5451557630},{"date":"2021-03-19","current":30.222173,"twenty":16.146147,"median":20.191936,"eighty":30.619304,"marketCap":5470213373},{"date":"2021-03-26","current":30.595804,"twenty":16.155113,"median":20.208951,"eighty":30.618171,"marketCap":5537840438},{"date":"2021-04-01","current":30.605466,"twenty":16.155113,"median":20.23058,"eighty":30.618171,"marketCap":5539589413},{"date":"2021-04-09","current":30.682769,"twenty":16.146147,"median":20.256725,"eighty":30.624072,"marketCap":5553581220},{"date":"2021-04-16","current":30.421872,"twenty":16.146147,"median":20.279169,"eighty":30.659957,"marketCap":5506358873},{"date":"2021-04-23","current":30.705316,"twenty":16.146147,"median":20.301119,"eighty":30.68362,"marketCap":5557662164},{"date":"2021-04-30","current":30.296255,"twenty":16.155113,"median":20.344302,"eighty":30.707893,"marketCap":5483622187},{"date":"2021-05-07","current":25.569844,"twenty":16.155113,"median":20.376409,"eighty":30.707893,"marketCap":5794126672},{"date":"2021-05-14","current":25.399722,"twenty":16.199938,"median":20.42789,"eighty":30.707893,"marketCap":5755577038},{"date":"2021-05-21","current":24.309395,"twenty":16.338001,"median":20.491036,"eighty":30.707893,"marketCap":5508508935},{"date":"2021-05-28","current":24.613553,"twenty":16.445582,"median":20.602521,"eighty":30.707893,"marketCap":5577431007},{"date":"2021-06-04","current":24.257843,"twenty":16.445582,"median":20.635149,"eighty":30.707893,"marketCap":5496827228},{"date":"2021-06-11","current":23.729434,"twenty":16.445582,"median":20.724193,"eighty":30.707893,"marketCap":5377089732},{"date":"2021-06-18","current":22.296285,"twenty":16.445582,"median":20.784488,"eighty":30.707893,"marketCap":5052338277},{"date":"2021-06-25","current":23.739744,"twenty":16.445582,"median":20.844829,"eighty":30.707893,"marketCap":5379426073},{"date":"2021-07-02","current":24.116075,"twenty":16.637435,"median":20.901381,"eighty":30.707893,"marketCap":5464702534},{"date":"2021-07-09","current":24.409922,"twenty":17.169936,"median":20.986777,"eighty":30.707893,"marketCap":5531288264},{"date":"2021-07-16","current":23.314439,"twenty":17.256001,"median":21.022105,"eighty":30.707893,"marketCap":5283051990},{"date":"2021-07-23","current":23.799029,"twenty":17.256001,"median":21.108637,"eighty":30.707893,"marketCap":5392860036},{"date":"2021-07-30","current":16.221256,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5679061858},{"date":"2021-08-06","current":16.529487,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5786973465},{"date":"2021-08-13","current":17.085494,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5981631539},{"date":"2021-08-20","current":16.514415,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5781696589},{"date":"2021-08-27","current":17.391968,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":6088928007},{"date":"2021-09-03","current":16.290002,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5703129776},{"date":"2021-09-10","current":15.723947,"twenty":15.757032,"median":21.108637,"eighty":30.707893,"marketCap":5504953785},{"date":"2021-09-17","current":15.378954,"twenty":15.742757,"median":21.108637,"eighty":30.707893,"marketCap":5384171968},{"date":"2021-09-24","current":15.594993,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5459807184},{"date":"2021-10-01","current":16.263207,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5693748664},{"date":"2021-10-08","current":16.043818,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5616940810},{"date":"2021-10-15","current":15.605042,"twenty":15.643409,"median":21.108637,"eighty":30.707893,"marketCap":5463325101},{"date":"2021-10-22","current":15.794285,"twenty":15.639757,"median":21.108637,"eighty":30.707893,"marketCap":5529579204},{"date":"2021-10-29","current":14.76593,"twenty":15.597281,"median":21.108637,"eighty":30.707893,"marketCap":6055507796},{"date":"2021-11-05","current":15.208034,"twenty":15.546124,"median":21.108637,"eighty":30.707893,"marketCap":6236814727},{"date":"2021-11-12","current":15.298251,"twenty":15.518993,"median":21.108637,"eighty":30.707893,"marketCap":6273812781},{"date":"2021-11-19","current":14.851461,"twenty":15.463133,"median":21.108637,"eighty":30.707893,"marketCap":6090584325},{"date":"2021-11-26","current":14.333071,"twenty":15.432575,"median":21.108637,"eighty":30.707893,"marketCap":5877992336},{"date":"2021-12-03","current":14.039507,"twenty":15.386249,"median":21.108637,"eighty":30.707893,"marketCap":5757601844},{"date":"2021-12-10","current":14.812797,"twenty":15.373275,"median":21.108637,"eighty":30.707893,"marketCap":6074728017},{"date":"2021-12-17","current":13.748807,"twenty":15.338429,"median":21.108637,"eighty":30.707893,"marketCap":5638385894},{"date":"2021-12-23","current":14.274358,"twenty":15.317813,"median":21.108637,"eighty":30.707893,"marketCap":5853914237},{"date":"2021-12-31","current":14.567922,"twenty":15.293897,"median":21.108637,"eighty":30.707893,"marketCap":5974304729},{"date":"2022-01-07","current":15.013279,"twenty":15.255263,"median":21.086933,"eighty":30.706604,"marketCap":6156945913},{"date":"2022-01-14","current":15.296819,"twenty":15.234158,"median":21.086933,"eighty":30.706604,"marketCap":6273225510},{"date":"2022-01-21","current":14.26147,"twenty":15.159469,"median":21.086933,"eighty":30.706604,"marketCap":5848628801},{"date":"2022-01-28","current":13.473236,"twenty":15.141331,"median":21.086933,"eighty":30.706604,"marketCap":5866246922},{"date":"2022-02-04","current":13.791554,"twenty":15.108005,"median":21.086933,"eighty":30.706604,"marketCap":6004842805},{"date":"2022-02-11","current":13.714672,"twenty":15.072408,"median":21.086933,"eighty":30.706604,"marketCap":5971368375},{"date":"2022-02-18","current":13.760532,"twenty":15.03684,"median":21.086933,"eighty":30.706604,"marketCap":5991335579},{"date":"2022-02-25","current":13.698487,"twenty":15.01748,"median":21.086933,"eighty":30.706604,"marketCap":5964321127},{"date":"2022-03-04","current":13.275413,"twenty":15.000697,"median":21.086933,"eighty":30.706604,"marketCap":5780114910},{"date":"2022-03-11","current":13.404745,"twenty":14.95296,"median":21.086933,"eighty":30.706604,"marketCap":5836425811},{"date":"2022-03-18","current":14.316596,"twenty":14.909849,"median":21.086933,"eighty":30.706604,"marketCap":6233446103},{"date":"2022-03-25","current":14.323128,"twenty":14.844637,"median":21.086933,"eighty":30.706604,"marketCap":6236290088},{"date":"2022-04-01","current":14.200329,"twenty":14.811668,"median":21.086933,"eighty":30.706604,"marketCap":6182823172},{"date":"2022-04-08","current":13.370779,"twenty":14.787157,"median":21.086933,"eighty":30.706604,"marketCap":5821637090},{"date":"2022-04-14","current":13.605352,"twenty":14.765711,"median":21.086933,"eighty":30.706604,"marketCap":5923770233},{"date":"2022-04-22","current":13.520383,"twenty":14.746344,"median":21.086933,"eighty":30.706604,"marketCap":5886774696},{"date":"2022-04-29","current":12.486253,"twenty":14.722676,"median":21.019089,"eighty":30.706604,"marketCap":5394061408},{"date":"2022-05-06","current":12.456696,"twenty":14.697062,"median":20.987955,"eighty":30.706604,"marketCap":5381292864},{"date":"2022-05-13","current":11.781959,"twenty":14.669658,"median":20.987955,"eighty":30.706604,"marketCap":5089806167},{"date":"2022-05-20","current":11.653499,"twenty":14.65307,"median":20.987955,"eighty":30.706604,"marketCap":5034311584},{"date":"2022-05-27","current":12.38533,"twenty":14.632214,"median":20.987955,"eighty":30.706604,"marketCap":5350462540},{"date":"2022-06-03","current":12.325642,"twenty":14.611294,"median":20.987955,"eighty":30.706604,"marketCap":5324677178},{"date":"2022-06-10","current":11.976595,"twenty":14.57907,"median":20.987955,"eighty":30.706604,"marketCap":5173888868},{"date":"2022-06-17","current":10.930751,"twenty":14.551074,"median":20.987955,"eighty":30.706604,"marketCap":4722084488},{"date":"2022-06-24","current":11.496493,"twenty":14.512301,"median":20.989133,"eighty":30.707893,"marketCap":4966484872},{"date":"2022-07-01","current":11.448483,"twenty":14.475592,"median":20.989133,"eighty":30.707893,"marketCap":4945744472},{"date":"2022-07-08","current":11.682046,"twenty":14.446312,"median":20.989133,"eighty":30.707893,"marketCap":5046643714},{"date":"2022-07-15","current":11.634035,"twenty":14.405366,"median":20.901381,"eighty":30.707893,"marketCap":5025903314},{"date":"2022-07-22","current":12.2945,"twenty":14.378471,"median":20.826627,"eighty":30.707893,"marketCap":5311223946},{"date":"2022-07-29","current":10.048078,"twenty":14.354753,"median":20.788925,"eighty":30.707893,"marketCap":5545534406},{"date":"2022-08-05","current":10.145269,"twenty":14.322523,"median":20.788925,"eighty":30.707893,"marketCap":5599173918},{"date":"2022-08-12","current":10.721601,"twenty":14.301896,"median":20.788925,"eighty":30.707893,"marketCap":5917251426},{"date":"2022-08-19","current":10.554902,"twenty":14.25908,"median":20.788925,"eighty":30.707893,"marketCap":5825250171},{"date":"2022-08-26","current":9.974504,"twenty":14.187553,"median":20.788925,"eighty":30.707893,"marketCap":5504928730},{"date":"2022-09-02","current":9.465258,"twenty":14.135304,"median":20.788925,"eighty":30.707893,"marketCap":5223876117},{"date":"2022-09-09","current":9.759015,"twenty":14.102002,"median":20.788925,"eighty":30.707893,"marketCap":5386000279},{"date":"2022-09-16","current":9.233506,"twenty":14.059394,"median":20.788925,"eighty":30.707893,"marketCap":5095971933},{"date":"2022-09-23","current":8.782199,"twenty":14.031264,"median":20.788925,"eighty":30.707893,"marketCap":4846895366},{"date":"2022-09-30","current":8.898075,"twenty":13.970918,"median":20.788925,"eighty":30.707893,"marketCap":4910847458},{"date":"2022-10-07","current":9.505917,"twenty":13.919195,"median":20.788925,"eighty":30.707893,"marketCap":5246315447},{"date":"2022-10-14","current":9.625859,"twenty":13.853034,"median":20.788925,"eighty":30.707893,"marketCap":5312511472},{"date":"2022-10-21","current":10.108676,"twenty":13.814554,"median":20.788925,"eighty":30.707893,"marketCap":5578978520},{"date":"2022-10-28","current":14.974971,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5630588980},{"date":"2022-11-04","current":15.463609,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5814316860},{"date":"2022-11-11","current":15.563653,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5851933626},{"date":"2022-11-18","current":15.647273,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5883374505},{"date":"2022-11-25","current":16.044465,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":6032718681},{"date":"2022-12-02","current":15.78614,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5935588822},{"date":"2022-12-09","current":14.866328,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5589739152},{"date":"2022-12-16","current":14.373571,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5404462543},{"date":"2022-12-23","current":14.855875,"twenty":13.814554,"median":20.344302,"eighty":30.707893,"marketCap":5585809042},{"date":"2022-12-30","current":14.999223,"twenty":13.814554,"median":19.765377,"eighty":30.707893,"marketCap":5639707692},{"date":"2023-01-06","current":15.569626,"twenty":13.814554,"median":19.464991,"eighty":30.682769,"marketCap":5854179403},{"date":"2023-01-13","current":16.083288,"twenty":13.814554,"median":19.115452,"eighty":30.607602,"marketCap":6047316232},{"date":"2023-01-20","current":16.159441,"twenty":13.814554,"median":18.427296,"eighty":30.461812,"marketCap":6075949889},{"date":"2023-01-27","current":15.870494,"twenty":13.814554,"median":17.1977,"eighty":30.416074,"marketCap":6365655133},{"date":"2023-02-03","current":16.700552,"twenty":13.814554,"median":17.005108,"eighty":30.370928,"marketCap":6698591585},{"date":"2023-02-10","current":16.651561,"twenty":13.814554,"median":16.756543,"eighty":30.27693,"marketCap":6678941035},{"date":"2023-02-17","current":16.851727,"twenty":13.814554,"median":16.756543,"eighty":30.179893,"marketCap":6759227566},{"date":"2023-02-24","current":16.526982,"twenty":13.814554,"median":16.695284,"eighty":30.105575,"marketCap":6628972495},{"date":"2023-03-03","current":17.355997,"twenty":13.814554,"median":16.651561,"eighty":29.955493,"marketCap":6961490255},{"date":"2023-03-10","current":15.566371,"twenty":13.814554,"median":16.584753,"eighty":29.755722,"marketCap":6243671220},{"date":"2023-03-17","current":15.480547,"twenty":13.814554,"median":16.531531,"eighty":29.517526,"marketCap":6209247509},{"date":"2023-03-24","current":14.869936,"twenty":13.814554,"median":16.458394,"eighty":29.346477,"marketCap":5964331266},{"date":"2023-03-31","current":15.968755,"twenty":13.81764,"median":16.370108,"eighty":29.233228,"marketCap":6405067639},{"date":"2023-04-06","current":16.098193,"twenty":13.814554,"median":16.263207,"eighty":29.165128,"marketCap":6456985367},{"date":"2023-04-13","current":16.098193,"twenty":13.811468,"median":16.213847,"eighty":29.047766,"marketCap":6456985367},{"date":"2023-04-21","current":11.256514,"twenty":13.795287,"median":16.167243,"eighty":28.957812,"marketCap":4514987632},{"date":"2023-04-28","current":10.547063,"twenty":13.769342,"median":16.098193,"eighty":28.929603,"marketCap":4230427133},{"date":"2023-05-05","current":9.97455,"twenty":13.75401,"median":16.098193,"eighty":28.929603,"marketCap":4000792069},{"date":"2023-05-12","current":10.85153,"twenty":13.72131,"median":16.043818,"eighty":28.869244,"marketCap":4360144650},{"date":"2023-05-19","current":10.855892,"twenty":13.715462,"median":15.968755,"eighty":28.809081,"marketCap":4361897590},{"date":"2023-05-26","current":10.676792,"twenty":13.696628,"median":15.930768,"eighty":28.764729,"marketCap":4289934926},{"date":"2023-06-02","current":10.354878,"twenty":13.660339,"median":15.878021,"eighty":28.764729,"marketCap":4160590154},{"date":"2023-06-09","current":11.276849,"twenty":13.620925,"median":15.820484,"eighty":28.752181,"marketCap":4531038118},{"date":"2023-06-16","current":11.224609,"twenty":13.575222,"median":15.789127,"eighty":28.740612,"marketCap":4510047958},{"date":"2023-06-23","current":11.398273,"twenty":13.554976,"median":15.774827,"eighty":28.742195,"marketCap":4579826058},{"date":"2023-06-30","current":12.275063,"twenty":13.534076,"median":15.748467,"eighty":28.744691,"marketCap":4932120371},{"date":"2023-07-07","current":12.273651,"twenty":13.517745,"median":15.73232,"eighty":28.744691,"marketCap":4931553069},{"date":"2023-07-14","current":12.851119,"twenty":13.480736,"median":15.69546,"eighty":28.744691,"marketCap":5163579436},{"date":"2023-07-21","current":13.091142,"twenty":13.444539,"median":15.669077,"eighty":28.744691,"marketCap":5260020713},{"date":"2023-07-28","current":28.047249,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5306539447},{"date":"2023-08-04","current":27.615476,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5224848012},{"date":"2023-08-11","current":26.895854,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5088695621},{"date":"2023-08-18","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":4907159099},{"date":"2023-08-25","current":26.047301,"twenty":13.437725,"median":15.657467,"eighty":28.735863,"marketCap":4928149259},{"date":"2023-09-01","current":27.32163,"twenty":13.437725,"median":15.657467,"eighty":28.633914,"marketCap":5169252452},{"date":"2023-09-08","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.427306,"marketCap":4907159099},{"date":"2023-09-15","current":26.131256,"twenty":13.437725,"median":15.657467,"eighty":28.310023,"marketCap":4944033705},{"date":"2023-09-22","current":25.732466,"twenty":13.437725,"median":15.657467,"eighty":28.103852,"marketCap":4868582588},{"date":"2023-09-29","current":26.778916,"twenty":13.437725,"median":15.657467,"eighty":28.040876,"marketCap":5066570857},{"date":"2023-10-06","current":25.921367,"twenty":13.437725,"median":15.657467,"eighty":27.952179,"marketCap":4904322591},{"date":"2023-10-13","current":26.404113,"twenty":13.437725,"median":15.657467,"eighty":27.770815,"marketCap":4995658153},{"date":"2023-10-20","current":25.186753,"twenty":13.437725,"median":15.657467,"eighty":27.598634,"marketCap":4765333692},{"date":"2023-10-27","current":17.482305,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5309375955},{"date":"2023-11-03","current":18.634591,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5659325216},{"date":"2023-11-10","current":18.896496,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5738865978},{"date":"2023-11-17","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-11-24","current":20.363168,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6184294245},{"date":"2023-12-01","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-12-08","current":19.455852,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5908742320},{"date":"2023-12-15","current":20.419291,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6201338694},{"date":"2023-12-22","current":21.33222,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6478595064},{"date":"2023-12-29","current":22.136644,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6722898833},{"date":"2024-01-05","current":21.592254,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6557567678},{"date":"2024-01-12","current":21.081538,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6402463192},{"date":"2024-01-19","current":21.749398,"twenty":13.417543,"median":15.643553,"eighty":27.632621,"marketCap":6605292135},{"date":"2024-01-26","current":21.257389,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6455869132},{"date":"2024-02-02","current":28.058844,"twenty":13.419632,"median":15.669077,"eighty":27.669555,"marketCap":7180258215},{"date":"2024-02-09","current":28.169854,"twenty":13.419632,"median":15.704121,"eighty":27.796495,"marketCap":7208665630},{"date":"2024-02-16","current":27.308418,"twenty":13.419632,"median":15.733099,"eighty":27.825797,"marketCap":6988224090},{"date":"2024-02-23","current":27.148564,"twenty":13.419632,"median":15.755466,"eighty":27.825797,"marketCap":6947317412},{"date":"2024-03-01","current":27.092062,"twenty":13.441726,"median":15.777181,"eighty":27.812943,"marketCap":6932858665},{"date":"2024-03-08","current":29.888075,"twenty":13.445242,"median":15.789127,"eighty":27.963376,"marketCap":7648358285},{"date":"2024-03-15","current":28.812755,"twenty":13.445242,"median":15.827779,"eighty":28.043716,"marketCap":7373184090},{"date":"2024-03-22","current":30.106708,"twenty":13.445242,"median":15.896443,"eighty":28.076477,"marketCap":7704306565},{"date":"2024-03-28","current":30.093322,"twenty":13.445242,"median":15.930965,"eighty":28.169854,"marketCap":7700881160},{"date":"2024-04-05","current":30.22941,"twenty":13.444539,"median":15.993577,"eighty":28.367293,"marketCap":7735706111},{"date":"2024-04-12","current":30.521665,"twenty":13.444539,"median":16.063876,"eighty":28.550678,"marketCap":7810494118},{"date":"2024-04-19","current":28.866298,"twenty":13.444539,"median":16.098193,"eighty":28.738359,"marketCap":7386885709},{"date":"2024-04-26","current":38.231767,"twenty":13.445242,"median":16.102434,"eighty":28.817217,"marketCap":8219830006},{"date":"2024-05-03","current":37.612546,"twenty":13.445242,"median":16.172772,"eighty":28.907655,"marketCap":8086697428},{"date":"2024-05-10","current":38.354269,"twenty":13.445242,"median":16.221256,"eighty":29.130483,"marketCap":8246167924},{"date":"2024-05-17","current":38.702534,"twenty":13.445242,"median":16.290002,"eighty":29.281518,"marketCap":8321044752},{"date":"2024-05-24","current":38.854069,"twenty":13.445242,"median":16.385606,"eighty":29.401797,"marketCap":8353624746},{"date":"2024-05-31","current":39.239552,"twenty":13.454387,"median":16.514415,"eighty":29.631749,"marketCap":8436503678},{"date":"2024-06-07","current":37.902323,"twenty":13.473236,"median":16.552178,"eighty":29.829217,"marketCap":8148999521},{"date":"2024-06-14","current":38.593535,"twenty":13.469601,"median":16.648062,"eighty":29.922236,"marketCap":8297610020},{"date":"2024-06-21","current":37.928908,"twenty":13.465967,"median":16.735546,"eighty":30.031355,"marketCap":8154715310},{"date":"2024-06-28","current":38.468585,"twenty":13.455063,"median":16.771844,"eighty":30.093322,"marketCap":8270745814},{"date":"2024-07-05","current":38.447317,"twenty":13.455063,"median":16.814111,"eighty":30.119103,"marketCap":8266173184},{"date":"2024-07-12","current":38.896605,"twenty":13.455063,"median":16.946902,"eighty":30.175867,"marketCap":8362770008},{"date":"2024-07-15","current":39.090676,"twenty":13.455063,"median":17.002596,"eighty":30.222173,"marketCap":8404495263},{"date":"2024-08-02","current":36.716509,"twenty":13.443132,"median":17.163621,"eighty":30.257604,"marketCap":8848678588},{"date":"2024-08-09","current":34.544426,"twenty":13.474636,"median":17.391968,"eighty":30.380644,"marketCap":8325206621},{"date":"2024-08-16","current":35.878536,"twenty":13.516412,"median":18.180924,"eighty":30.441623,"marketCap":8646727108},{"date":"2024-08-23","current":35.80732,"twenty":13.536427,"median":18.692584,"eighty":30.507515,"marketCap":8629564092},{"date":"2024-08-30","current":37.015615,"twenty":13.564424,"median":19.093862,"eighty":30.613864,"marketCap":8920763252},{"date":"2024-09-06","current":35.370529,"twenty":13.617967,"median":19.465206,"eighty":30.68362,"marketCap":8524297599},{"date":"2024-09-13","current":35.593672,"twenty":13.654447,"median":19.770139,"eighty":30.724008,"marketCap":8578075046},{"date":"2024-09-20","current":36.657162,"twenty":13.697093,"median":19.955344,"eighty":30.811628,"marketCap":8834376075},{"date":"2024-09-27","current":37.647062,"twenty":13.718449,"median":20.170481,"eighty":31.202877,"marketCap":9072941988},{"date":"2024-10-04","current":37.063092,"twenty":13.754547,"median":20.419291,"eighty":33.022546,"marketCap":8932205262},{"date":"2024-10-11","current":36.813837,"twenty":13.782708,"median":20.788925,"eighty":33.919642,"marketCap":8872134709},{"date":"2024-10-18","current":38.748534,"twenty":13.844231,"median":21.132049,"eighty":34.498848,"marketCap":9338396624},{"date":"2024-10-25","current":35.731356,"twenty":13.972834,"median":21.270485,"eighty":35.063709,"marketCap":8611256876},{"date":"2024-10-31","current":35.156674,"twenty":14.041756,"median":21.392084,"eighty":35.155808,"marketCap":9249721045},{"date":"2024-11-08","current":37.821894,"twenty":14.04673,"median":21.716135,"eighty":35.381924,"marketCap":9950940184},{"date":"2024-11-15","current":37.830595,"twenty":14.04673,"median":21.871932,"eighty":35.703819,"marketCap":9953229467},{"date":"2024-11-22","current":39.842745,"twenty":14.04673,"median":22.117001,"eighty":35.842453,"marketCap":10482626124},{"date":"2024-11-29","current":39.607813,"twenty":14.04673,"median":22.252579,"eighty":36.21515,"marketCap":10420815487},{"date":"2024-12-06","current":38.322212,"twenty":14.04673,"median":22.415358,"eighty":36.508084,"marketCap":10082573948},{"date":"2024-12-13","current":36.138213,"twenty":14.04673,"median":22.859046,"eighty":36.698326,"marketCap":9507963955},{"date":"2024-12-20","current":33.179809,"twenty":14.04673,"median":23.30284,"eighty":36.698326,"marketCap":8729607789},{"date":"2024-12-27","current":34.026,"twenty":14.04673,"median":23.434298,"eighty":36.698326,"marketCap":8952240545},{"date":"2025-01-03","current":32.842638,"twenty":14.04673,"median":23.518071,"eighty":36.698326,"marketCap":8640898079},{"date":"2025-01-10","current":33.425618,"twenty":14.045235,"median":23.729434,"eighty":36.704639,"marketCap":8794280029},{"date":"2025-01-17","current":33.814996,"twenty":14.045235,"median":23.80934,"eighty":36.704639,"marketCap":8896725436},{"date":"2025-01-24","current":35.437768,"twenty":14.045235,"median":23.953686,"eighty":36.704639,"marketCap":9323676686},{"date":"2025-01-31","current":33.333263,"twenty":14.045235,"median":23.956263,"eighty":36.531348,"marketCap":9823312666},{"date":"2025-02-07","current":33.556598,"twenty":14.045235,"median":23.956263,"eighty":36.222746,"marketCap":9889129548},{"date":"2025-02-14","current":32.746766,"twenty":14.045235,"median":23.956263,"eighty":35.878536,"marketCap":9650471812},{"date":"2025-02-21","current":33.306075,"twenty":14.045235,"median":23.956263,"eighty":35.814441,"marketCap":9815300176},{"date":"2025-02-28","current":31.197014,"twenty":14.045235,"median":23.956263,"eighty":35.764062,"marketCap":9193759885},{"date":"2025-03-07","current":29.524826,"twenty":14.045214,"median":23.954974,"eighty":35.772714,"marketCap":8700966306},{"date":"2025-03-14","current":29.365117,"twenty":14.045214,"median":23.967817,"eighty":35.772714,"marketCap":8653899927},{"date":"2025-03-21","current":29.877642,"twenty":14.045214,"median":24.116075,"eighty":35.772714,"marketCap":8804941148},{"date":"2025-03-28","current":30.412112,"twenty":14.045214,"median":24.170205,"eighty":35.772714,"marketCap":8962449399},{"date":"2025-04-04","current":28.45369,"twenty":14.045214,"median":24.30281,"eighty":35.772714,"marketCap":8385302378},{"date":"2025-04-11","current":27.414009,"twenty":14.045235,"median":24.43312,"eighty":35.764062,"marketCap":8078908592},{"date":"2025-04-15","current":27.562257,"twenty":14.045235,"median":24.451163,"eighty":35.764062,"marketCap":8122597011}],"updateTime":1744837431288}}}